Stacie S. Aarestad

Representative Experience

• Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a multi-state cannabis operator
  • in closing its previously announced private placement of 8% Senior Secured Notes due 2026 for aggregate gross proceeds of US$350 million 
  • in closing an underwritten public offering worth of approximately US$228 million of subordinate voting shares
  • in its C$115.5 million offering of subordinate voting shares
• Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases in a number of capital markets transactions, including:
  • an “at the market offering” program having an aggregate offering price of up to $50 million, with Cantor Fitzgerald & Co.
  • its underwritten public offering of 16,741,573 shares of its common stock, together with accompanying warrants to purchase 8,370,786 shares of common stock for gross proceeds of approximately $74.5 million
  • its sales agreement with Cantor Fitzgerald & Co. for an up to $25 million ATM offering
  • its $37.4 million underwritten public offering of common stock
• Organogenesis Holdings Inc. (Nasdaq: ORGO) in multiple capital markets transactions, including
  • $64.7 million underwritten public offering of Class A common stock
  • $50.3 million underwritten public offering of Class A common stock
  • in its warrant exchange offer and consent solicitation
  • a SPAC IPO/reverse merger of Organogenesis Inc. with and into a wholly owned subsidiary of Avista Healthcare Public Acquisition Corp. (AHPAC), with Organogenesis Inc. surviving the merger and AHPAC changing its name to Organogenesis Holdings Inc.
• Sensata Technologies, Inc., an indirect, wholly owned subsidiary of Sensata Technologies Holding plc (NYSE: ST), in its Rule 144A offering of $450 million in aggregate principal amount of 4.375% senior notes due 2030
• Good Start Genetics in a merger with genetic information company Invitae Corporation (NYSE: NVTA)
• Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA) in its initial public offering of common stock 
• Zosano Pharma Corporation (Nasdaq: ZSAN):
• • $50.0 million underwritten public offering of common stock
  • $29.3 million underwritten public offering of common stock
  • $7.5 million PIPE of units (common stock and warrants) with warrants exercisable for an additional $14.4 million
• Dyax Corp. (Nasdaq: DYAX) in its sale to Shire plc.
• Dyax Corp. in public securities offerings including:
  • $230,000,000 underwritten public offering of common stock
  • $80,000,000 underwritten public offering of common stock
  • $65,000,000 underwritten public offering of common stock
  • $30,000,000 registered direct offering of common stock
  • $63,537,500 underwritten public offering of common stock
  • $21,000,000 underwritten public offering of common stock
  • $17,250,000 underwritten public offering of common stock
  • $50,000,000 Committed Equity Financing Facility with Azimuth Opportunity Ltd.
  • $44,300,000 underwritten public offering of common stock
• Dyax Corp. in connection with secured loans including:
  • $65,000,000 loan agreement with Cowen Healthcare Royalty Partners, L.P., consisting of a $50,000,000 Tranche A loan and a $15,000,000 Tranche B loan, secured by Dyax’s phage display Licensing and Funded Research Program
  • $30,000,000 royalty interest assignment agreement with Paul Capital Partners
• Bolt Technology Corporation (Nasdaq: BOLT) in its sale to Teledyne Technologies Incorporated (NYSE: TDY)
• NewStar Financial, Inc. (Nasdaq: NEWS) in securities offerings:
  • $300,000,000 144A offering of 7.25% Senior Notes due 2020
  • $125,000,000 PIPE with institutional investors including, Corsair Capital, Union Square Partners and Och-Ziff Capital Management, Swiss Re and SAB Capital
• Lamar Advertising Company (Nasdaq: LAMR) in its REIT conversion
• Lamar Advertising Company and its wholly owned subsidiary Lamar Media Corp. in high yield and convertible debt offerings and tender offers including:
  • $400,000,000 144A offering of 5 3/4% Senior Notes due 2026
  • $510,000,000 144A offering of 5 ⅜% Senior Notes due 2024 with follow-on exchange offer
  • $535,000,000 144A offering of 5% Senior Subordinated Notes due 2023 with follow-on exchange offer
  • $500,000,000 144A offering of 5 ⅞% Senior Subordinated Notes due 2022 with follow-on exchange offer
  • $400,000,000 144A offering of 7 ⅞% Senior Subordinated Notes due 2018 with follow-on exchange offer
  • Cash Tender Offer and Consent Solicitation for all of Lamar’s then outstanding 7 ¼% Senior Subordinated Notes due 2013
  • Tender Offer to eligible employees and directors to exchange certain outstanding options to purchase the Company's Class A common stock for a lesser number of new options
  • Cash Tender Offers for all of Lamar’s then outstanding 2 ⅞% Convertible Notes due 2010—Series B
  • $350,000,000 144A offering of 9 ¾% Senior Notes due 2014 with follow-on exchange offer
  • $275,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series C with follow-on exchange offer
  • Exchange Offer of a new series of 2 ⅞% Convertible Notes due 2010—Series B for all outstanding 2 ⅞% Convertible Notes due 2010
  • $216,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series B with follow-on exchange offer
  • $400,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015 with follow-on exchange offer